Japan Ships First Batch Of Mpox Vaccines To DRC

Initial 50,000 Doses As Cases Persist

Japan ships the first batch of 50,000 mpox vaccine doses to DRC after training local healthcare providers dealing with the persistent outbreak.

Japan ships 50,000 vaccine doses to DRC as mpox cases persist in the central African country. (Shutterstock)

Japan has shipped the first 50,000 doses of a major donation of a domestically developed mpox vaccine to the Democratic Republic of the Congo (DRC), following a supply request from the hard-hit central African nation last year for a total of 3,050,000 doses.

More from Japan

Japan Expands Priority R&D List For Regular Vaccinations

 
• By 

Japan adds four new pediatric vaccines, including for MMRV and norovirus, to a list of priority vaccines eligible for assistance in regulatory processing.

Japan Recommends Beyonttra, Raises Enhertu Price

 
• By 

Japan recommends eight new drugs for approval, including two for cardiomyopathy, and will also raise prices for multiple products, including Enhertu, on 1 April.

Japan PM Delays Revision Of High-Cost Healthcare Benefit After Patient Protests

 
• By 

A plan to reduce benefits under Japan's financial safety net for patients contributing to the costs of their long-term medical care is being reconsidered by the government following protests from patient and doctor groups.

Opposition Tempers Cuts To Japan’s High-Cost Healthcare Benefits

 
• By 

Japan's MHLW has decided to tone down planned policy revisions that would have cut benefits under a patient support scheme for high-priced drugs, after resistance from patient groups.

More from Vaccines

Makary US FDA Nomination Advances, Last Minute Hiccup May Offer Clues On Mifepristone

 

President Trump’s CDC director nominee was pulled after vaccine positions appeared too extreme for some Republicans, but the nominations to lead the FDA and NIH advanced to the Senate floor despite last-minute drama.

Senators Scrutinize US FDA Commissioner Nominee Makary Over VRBPAC Cancellation

 
• By 

Martin Makary said he would re-evaluate the topics that deserve a Vaccines and Related Biological Products Advisory Committee review, but did not commit to rescheduling the cancelled meeting on influenza vaccine strain selection.

Science Vs. Politics: Hearing Could Reveal Makary’s Approach To Unusual Administration Involvement

 

US FDA Commissioner nominee Martin Makary’s 6 March Senate confirmation hearing should offer insight on his alignment with HHS Secretary Robert F. Kennedy Jr.'s views and willingness to insulate the FDA from an unusual level of micromanagement by the department and White House.